Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ALQA's Cash to Debt is ranked higher than
99% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. ALQA: No Debt )
ALQA' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.82
ALQA's Equity to Asset is ranked higher than
89% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ALQA: 0.82 )
ALQA' s 10-Year Equity to Asset Range
Min: 0.64   Max: 0.99
Current: 0.82

0.64
0.99
F-Score: 5
Z-Score: 3.44
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1119.69
ALQA's Operating margin (%) is ranked lower than
54% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. ALQA: -1119.69 )
ALQA' s 10-Year Operating margin (%) Range
Min: -1119.69   Max: -51.07
Current: -1119.69

-1119.69
-51.07
Net-margin (%) -1222.30
ALQA's Net-margin (%) is ranked lower than
54% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.98 vs. ALQA: -1222.30 )
ALQA' s 10-Year Net-margin (%) Range
Min: -1222.3   Max: -52.73
Current: -1222.3

-1222.3
-52.73
ROE (%) -157.51
ALQA's ROE (%) is ranked lower than
53% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ALQA: -157.51 )
ALQA' s 10-Year ROE (%) Range
Min: -1388.89   Max: -11.7
Current: -157.51

-1388.89
-11.7
ROA (%) -125.93
ALQA's ROA (%) is ranked lower than
55% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ALQA: -125.93 )
ALQA' s 10-Year ROA (%) Range
Min: -2490.27   Max: -11.39
Current: -125.93

-2490.27
-11.39
ROC (Joel Greenblatt) (%) -1153.70
ALQA's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. ALQA: -1153.70 )
ALQA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -143800   Max: -28.01
Current: -1153.7

-143800
-28.01
Revenue Growth (%) -12.30
ALQA's Revenue Growth (%) is ranked higher than
56% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ALQA: -12.30 )
ALQA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -12.3
Current: -12.3

EBITDA Growth (%) 62.90
ALQA's EBITDA Growth (%) is ranked higher than
97% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.40 vs. ALQA: 62.90 )
ALQA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 106.5
Current: 62.9

0
106.5
EPS Growth (%) 53.40
ALQA's EPS Growth (%) is ranked higher than
96% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ALQA: 53.40 )
ALQA' s 10-Year EPS Growth (%) Range
Min: -46.8   Max: 113.8
Current: 53.4

-46.8
113.8
» ALQA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.97
ALQA's P/B is ranked higher than
67% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ALQA: 2.97 )
ALQA' s 10-Year P/B Range
Min: 2.87   Max: 1487.5
Current: 2.97

2.87
1487.5
P/S 23.48
ALQA's P/S is ranked lower than
73% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. ALQA: 23.48 )
ALQA' s 10-Year P/S Range
Min: 4.65   Max: 39.22
Current: 23.48

4.65
39.22
EV-to-EBIT -2.46
ALQA's EV-to-EBIT is ranked higher than
58% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. ALQA: -2.46 )
ALQA' s 10-Year EV-to-EBIT Range
Min: 0.5   Max: 1.3
Current: -2.46

0.5
1.3
Current Ratio 6.70
ALQA's Current Ratio is ranked higher than
92% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. ALQA: 6.70 )
ALQA' s 10-Year Current Ratio Range
Min: 0.04   Max: 96.93
Current: 6.7

0.04
96.93
Quick Ratio 6.45
ALQA's Quick Ratio is ranked higher than
94% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. ALQA: 6.45 )
ALQA' s 10-Year Quick Ratio Range
Min: 0.04   Max: 96.93
Current: 6.45

0.04
96.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.09
ALQA's Price/Net Cash is ranked higher than
95% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ALQA: 5.09 )
ALQA' s 10-Year Price/Net Cash Range
Min: 5.3   Max: 984.4
Current: 5.09

5.3
984.4
Price/Net Current Asset Value 4.86
ALQA's Price/Net Current Asset Value is ranked higher than
93% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ALQA: 4.86 )
ALQA' s 10-Year Price/Net Current Asset Value Range
Min: 5.06   Max: 984.4
Current: 4.86

5.06
984.4
Price/Tangible Book 4.29
ALQA's Price/Tangible Book is ranked higher than
77% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.39 vs. ALQA: 4.29 )
ALQA' s 10-Year Price/Tangible Book Range
Min: 4.46   Max: 984.4
Current: 4.29

4.46
984.4
Price/Median PS Value 2.09
ALQA's Price/Median PS Value is ranked higher than
57% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ALQA: 2.09 )
ALQA' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 3.12
Current: 2.09

0.57
3.12
Forward Rate of Return (Yacktman) 75.94
ALQA's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. ALQA: 75.94 )
ALQA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 75.6   Max: 11208.4
Current: 75.94

75.6
11208.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Alliqua, Inc., a Florida corporation formed on October 21, 1997. The Company is a biomedical company that does business through its wholly owned subsidiaries. It develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. Its subsidiary AquaMed Technologies, Inc. manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. Its SilverSeal and Hydress dressings are each available in two sizes. They are used to provide and maintain a moist wound environment. The benefits of these products include reduced scarring and pain, greater speed of healing and increased absorption of exudate (fluid that filters from the circulatory system into lesions or areas of inflammation). SilverSeal dressings also provide an antimicrobial barrier. Silver based wound dressings are becoming increasingly prevalent in wound care due to the recent increase of antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus, known as MRSA. Its main competitor in the high performance gel industry is Covidien plc. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U.S. and other countries.
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Alliqua BioMedical to Present at Upcoming Investor Conferences Sep 02 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 29 2014
ALLIQUA BIOMEDICAL, INC. Financials Aug 19 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
Alliqua Biomedical, Inc. Reports Second Quarter 2014 Financial Results Aug 11 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jul 22 2014
Alliqua BioMedical Announces Changes to Its Board of Directors Jul 22 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Jul 21 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 10 2014
Alliqua BioMedical's CEO Issues Midyear Corporate Update for Shareholders Jul 10 2014
Alliqua BioMedical Added to the Russell Microcap(R) Index Jun 30 2014
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Jun 11 2014
Alliqua Reincorporates in State of Delaware, De-Staggers Board and Changes Name to Alliqua... Jun 11 2014
UPDATE: Ascendiant Capital Markets Initiates Coverage On Alliqua As Turnaround Story Warrants Fresh... Jun 04 2014
A Celgene Satellite: An Interview With Alliqua CEO Dave Johnson Jun 04 2014
Substance Over Style: How Niche Companies Alliqua And Horizon Are Being Overlooked May 29 2014
Alliqua Strengthens Balance Sheet, Launches Biovance, and Makes Its First Acquisition May 28 2014
Nasdaq stocks posting largest percentage increases May 20 2014
ALLIQUA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 12 2014
Alliqua reports Q1 EPS (73c), consensus (40c) May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK